FindTrial
Sign In

AMXT 1501 Dicaprate

DRUG2 trials

Sponsors

Milton S. Hershey Medical Center, Aminex Therapeutics, Inc.

Conditions

Atypical Teratoid/Rhabdoid TumorDIPG Brain TumorDiffuse Intrinsic Pontine GliomaEmbryonal Tumor With Multilayered RosettesEwing SarcomaHER2-low Hormone Receptor Positive Breast CancerMelanoma (Skin Cancer)Neuroblastoma

Phase 1

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingNCT06465199
Milton S. Hershey Medical CenterAtypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, DIPG Brain Tumor +4
Start: 2026-05-13End: 2035-05-01Target: 265Updated: 2026-09-03
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingNCT07287917
Aminex Therapeutics, Inc.HER2-low Hormone Receptor Positive Breast Cancer, Melanoma (Skin Cancer)
Start: 2026-01-26End: 2028-12-29Target: 92Updated: 2026-09-04

Related Papers

Abstract CT270: Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas
Cancer Research2026-04-17